Stockscreener 앱 받기
2.86
7.44%
-0.23
시장 영업 전:
2.86
Rocket Pharmaceuticals Inc 주식(RCKT)의 최신 뉴스
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
RCKT Deadline: RCKT Investors with Losses in Excess of $100K Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire
Rocket Pharmaceuticals, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before August 11, 2025 to Discuss Your RightsRCKT - PR Newswire
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals - Bluefield Daily Telegraph
RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire
RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action – RCKT - GlobeNewswire Inc.
Has Rocket Pharmaceuticals Inc. Equity Warrant found a price floorFree Scalable Portfolio Growth Suggestions - Newser
Is Rocket Pharmaceuticals Inc. Equity Warrant forming a reversal patternReversal Signal Prediction Based on Volume - Newser
What high frequency data says about Rocket Pharmaceuticals Inc.Weekly Gain Forecast with Momentum Indicators - Newser
Will breakout in Rocket Pharmaceuticals Inc. lead to full recoveryProfit Target Planning with Exit Confidence - Newser
Faruqi & Faruqi Reminds Rocket Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025RCKT - PR Newswire
RCKT DEADLINE ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class ActionRCKT - ACCESS Newswire
Rocket Pharmaceuticals and the Rocketing Risks in Biotech Innovation - AInvest
Faruqi & Faruqi Investigates Rocket Pharmaceuticals Securities Litigation - AInvest
Combining machine learning predictions for Rocket Pharmaceuticals Inc. Equity Warrant2-Day Signal Watch with Forecast Outcome - Newser
Should you wait for a breakout in Rocket Pharmaceuticals Inc.Profitable Trading Blueprint with Entry Zones - Newser
Custom watchlist performance reports with Rocket Pharmaceuticals Inc.Free Exit Ready Momentum Stock Watchlist - Newser
Rocket Pharmaceuticals Inc. Equity Warrant stock momentum explainedBreakout Watcher with Entry and Exit Alerts - Newser
Volume spikes in Rocket Pharmaceuticals Inc. stock – what they meanSafe Entry Screening with Data Backed Analysis - Newser
Class Action Lawsuit Filed: Rocket Pharmaceuticals, Inc. (RCKT)Join by August 11, 2025Contact Levi & Korsinsky - Stockhouse
Class Action Filed Against Rocket Pharmaceuticals, Inc. - GlobeNewswire
Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) Seeking Recovery for Investors – Contact Levi & Korsinsky - Morningstar
Rocket Pharmaceuticals and the Biotech Litigation Landscape: Navigating Risks in a High-Stakes Sector - AInvest
August 11, 2025 Deadline: Join Class Action Lawsuit Against Rocket Pharmaceuticals, Inc. (RCKT)Contact Levi & Korsinsky - Barchart.com
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class - GlobeNewswire
Rocket Pharmaceuticals stock price target raised to $3.00 from $2.50 at Jefferies - Investing.com Canada
Rocket Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
2025-08-07 | Securities Class Action Lawsuit Filed Against Rocket Pharmaceuticals, Inc. (RCKT)Levi & Korsinsky Represents Shareholders | NDAQ:RCKT | Press Release - Stockhouse
MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd - GlobeNewswire
Rocket Pharmaceuticals Announces Strategic Restructuring and Leadership Changes - TipRanks
Investors in Rocket Pharmaceuticals, Inc. Should Contact - GlobeNewswire
Rocket Pharmaceuticals, Inc. Investors: Please contact the - GlobeNewswire
Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress | RCKT Stock News - GuruFocus
Rocket (RCKT) Q2 Loss Narrows 16% - Nasdaq
Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress - Business Wire
RCKT DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, - GlobeNewswire
Deadline Alert: Rocket Pharmaceuticals, Inc. (RCKT) - GlobeNewswire
Lost Money on Rocket Pharmaceuticals, Inc.(RCKT)? Join Class Action Suit Seeking RecoveryContact The Gross Law Firm - Morningstar
Tools to monitor Rocket Pharmaceuticals Inc. Equity Warrant recovery probabilityLow Drawdown Picks with Weekly Updates - Newser
2025-08-06 | Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky Before August 11, 2025 to Join Class Action | NDAQ:RCKT | Press Release - Stockhouse
Did You Lose Money on Rocket Pharmaceuticals, Inc. (RCKT)? Levi & Korsinsky Urges Investors to Act Before August 11, 2025 - Barchart.com
Berger Montague Reminds Rocket Pharmaceuticals (RCKT) Investors With Substantial Losses to Inquire About a Securities Fraud Class Action by August 11, 2025 - TradingView
Rocket Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your RightsRCKT - NewMediaWire
Universal Beteiligungs und Servicegesellschaft mbH Invests $143,000 in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Shareholders of Rocket Pharmaceuticals, Inc. Should Contact - GlobeNewswire
Rocket Pharmaceuticals, Inc. (RCKT) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of August 11, 2025 Deadline - ACCESS Newswire
Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.
Evaluating Rocket Pharmaceuticals Inc. Equity Warrant with trendline analysisLow Risk Trade Timing with Analysis Metrics - Newser
DEADLINE NEXT WEEK: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - PR Newswire
DEADLINE ALERT for VSTS, RCKT, TEM, and DDD: The Law - GlobeNewswire
Is Rocket Pharmaceuticals Inc. stock ready for a breakoutBuy Candidate Summary Based on Fundamentals - Newser
Sector ETF performance correlation with Rocket Pharmaceuticals Inc.Daily Exit and Entry Price Prediction - Newser
What institutional flow reveals about Rocket Pharmaceuticals Inc.Buy/Sell Zone Confirmation Technical Analysis - Newser
0.24%
3.39%
자본화:
|
볼륨(24시간):